Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters first to patients and clinicians. It also gives investors a clinical signal worth examining without getting carried away.
A response rate that clears the usual bar
At the September 18, 2026 cutoff, 51 treated patients were evaluable for response. Thirty-two responded, including two complete responses and 30 partial responses, producing a 62.7% overall response rate. That is a striking figure beside the roughly 15% to 30% response rates historically associated with irinotecan and temozolomide alone in relapsed or refractory Ewing sarcoma. Historical comparisons are never a clean head-to-head fight, and anybody saying otherwise is selling something. Still, the gap is wide enough that it deserves attention.
The disease-control figure was 86.3%, with 12 additional patients achieving stable disease. More than that, 43 of 51 evaluable patients had measurable tumor shrinkage from baseline. In a heavily pretreated population, that kind of breadth is not just one or two exceptional cases dragging an average upward. It suggests the combination may be doing something meaningful across a material share of enrolled patients.
The data points that should not get buried
- Sixty patients, including nine adolescents, received ozekibart plus irinotecan and temozolomide; 22 remained on treatment at the cutoff.
- Median progression-free survival was 6.0 months, versus historical estimates of roughly 3 to 4 months for the chemotherapy backbone alone.
- Eighteen patients showed clinical benefit beyond six months, and one patient had an ongoing partial response lasting more than two years.
- Fourteen evaluable patients remained progression-free at cutoff, including two beyond 12 months.
Duration is where early oncology data either gains muscle or turns to vapor. A six-month median progression-free survival is not a cure, and the confidence interval of 4.6 to 7.4 months reminds us this remains a modest-sized study. But durable benefit in 18 patients, particularly the response extending beyond two years, is the sort of detail that makes the headline response rate harder to dismiss as a short-lived scan effect.
Safety and the regulatory divide matter just as much
Ozekibart is a tetravalent death receptor 5 agonist engineered to trigger tumor-biased cell death without the secondary crosslinking associated with earlier DR5 agents. The company says the combination's safety profile remained acceptable and manageable, consistent with the known toxicities of irinotecan, temozolomide, and DR5 agonism. It also reported no unexpected cumulative hepatotoxicity. Good. That is an important observation given the liver toxicity that haunted first-generation DR5 approaches. But “manageable” is not a substitute for a full safety table, and investors should wait for the CTOS presentation on November 19 before pretending the risk picture is fully settled.
Do not mash two indications into one valuation story
Inhibrx also has an FDA-accepted biologics license application for ozekibart in conventional chondrosarcoma. That is a separate regulatory track from Ewing sarcoma, and the distinction is not bookkeeping trivia. Acceptance for filing is not approval, while encouraging Ewing data are not a filing announcement. NASDAQ:INBX has potentially gained another compelling clinical pillar, but it has not removed the usual development, regulatory, reimbursement, and commercialization hazards.
The commercial math is also specialized rather than enormous: approximately 300 new U.S. Ewing sarcoma cases annually and an estimated 2,500 people living with the disease. That small population does not diminish the medical need one inch. It does mean the investment case rests on execution, potential regulatory flexibility, and whether ozekibart's activity can extend across sarcoma settings. For NASDAQ:INBX, this update is real ammunition. Just do not confuse ammunition with the battle being over.